Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.

CONTEXT New guidelines for HER2 testing have been introduced. OBJECTIVES To evaluate the difference in HER2 assessment after introduction of new cutoff levels for both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) and to compare interobserver agreement and time to score between image analysis and conventional microscopy. DESIGN Samples from 150 patients with breast cancer were scored by 7 pathologists using conventional microscopy, with a cutoff of both 10% and 30% IHC-stained cells, and using automated microscopy with image analysis. The IHC results were compared individually and to HER2 status as determined by FISH, using both the approved cutoff of 2.0 and the recently introduced cutoff of 2.2. RESULTS High concordance was found in IHC scoring among the 7 pathologists. The 30% cutoff led to slightly fewer positive IHC observations. Introduction of a FISH equivocal zone affected 4% of the FISH scores. If cutoff for FISH is kept at 2.0, no difference in patient selection is found between the 10% and the 30% IHC cutoff. Among the 150 breast cancer samples, the new 30% IHC and 2.2 FISH cutoff levels resulted in one case without a firm diagnosis because both IHC and FISH were equivocal. Automated microscopy and image analysis-assisted IHC led to significantly better interobserver agreement among the 7 pathologists, with an increase in mean scoring time of only about 30 seconds per slide. CONCLUSIONS The change in cutoff levels led to a higher concordance between IHC and FISH, but fewer samples were classified as HER2 positive.

[1]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[2]  K. Bloom,et al.  Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. , 2004, American journal of clinical pathology.

[3]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[4]  R. Gelber,et al.  Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. , 2008, The Lancet. Oncology.

[5]  T. Hastie,et al.  New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up , 2008, Breast Cancer Research and Treatment.

[6]  Matteo Brunelli,et al.  HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. , 2008, American journal of clinical pathology.

[7]  Marta Cuadros,et al.  Systematic Review of HER2 Breast Cancer Testing , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[8]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[9]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[10]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[11]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[12]  K. Nielsen,et al.  Human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[13]  Gaëtan MacGrogan,et al.  Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations , 2009, Modern Pathology.

[14]  T. Grogan,et al.  Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[17]  Mitch Dowsett,et al.  Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Arbushites,et al.  HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer , 2008, Clinical Cancer Research.

[19]  D. Hicks,et al.  HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. , 2008, American journal of clinical pathology.

[20]  H. Yaziji,et al.  Begin at the Beginning, With the Tissue!: The Key Message Underlying the ASCO/CAP Task-force Guideline Recommendations for HER2 Testing , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[21]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. N. Rao,et al.  Her‐2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her‐2/neu Polysomy , 2001, The breast journal.

[23]  J. Beneke,et al.  HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. , 2002, American journal of clinical pathology.

[24]  Nandini Dendukuri,et al.  Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis , 2007, Canadian Medical Association Journal.